Pair theory doesn't work. Some shorts could cover with calls, but there are not enough to cover anyway near 29 million shares. I like you don't see how it has stayed so high (near 30 million short) for so long. Makes no sense to me
doubt it. probably come into money as your name suggests on your back
Several years ago when NOK was $2-3 I said they should form a partnership with Apple and Microsoft and themselves (1/3 each) for the HERE mapping business. It still makes lots of sense. Stranger things have happened.
Companies like Apple or Microsoft and other US companies with overseas funds they don't want to repatriate because then they pay taxes, may pay more for a strategic asset with money that is just sitting there earning basically nothing.
Uber is unlikely to be the only company bidding for Here. Previous reports from Bloomberg and The Wall Street Journal have named a laundry list of companies that Nokia's been pitching to buy the piece of its business. That includes Apple, Amazon, Audi AG, BMW AG, Baidu, Facebook, Harman, Mercedes-Benz, and Sirius XM. Facebook's own interest in the company also got a little more complex this week after it began using Here's maps on its mobile site and on Android devices.
Friday shall tell us if Dodge and Cox is still selling. For the period ending 31 Dec 14 there was a decrease in institutional holdings of 70 million shares including almost 40 million decrease by D & C. I think this has kept downward pressure on the share price. I am hoping D & C are gone so this selling can finally cease.
NEJM article supportive of pathogen inactivation. Yesterday, the New England
Journal of Medicine (NEJM) published an opinion piece recommending an FDA
mandate of pathogen inactivation (PI) technology to improve blood safety. The
authors, blood transfusion experts from the American Red Cross and Yale, highlight
the advantages of PI over current reactive screening methods. We believe a
positive piece in a high-profile publication like NEJM could help increase industry
awareness and positively influence FDA’s thinking on the topic.
n Pathogen inactivation strongly endorsed by industry leaders in NEJM
- NEJM publication calls for PI mandate (available here): “Perspective” piece
encourages FDA to mandate PI in the screening of blood components. NEJM
is the most clinically relevant medical publication, in our view.
-Written by influential experts: Richard Benjamin (Chief Medical Officer of
American Red Cross), Susan Stramer (VP, Scientific Affairs, Biomedical
Services of American Red Cross), and Edward Snyder (Professor of
Laboratory Medicine and Director, Blood Bank at Yale University)
- Highlights need for PI: The article describes the limitations of the current
screening process, including its reactive approach to emerging pathogens and
relatively high false-negative rates. It also underscores the added cost and
logistical burdens associated with FDA’s recent draft guidance ( link to Baird
note; link to guidance), which the authors believe wouldn’t be implemented
without a mandate. We believe this further strengthens the case for PI
- PI as replacement for current screening: The authors state that PI could
eliminate bacterial detection, CMV screening, and irradiation (for
graft-versus-host disease), therefore reducing the costs associated with
existing screening methods (we believe this would be allowed by CERS’ FDA
labeling) and helping offset the cost of PI. Additionally, a proactive approach
using PI may diminish the dangers of emerging pathogens to the blood supply,
as noted by the authors.
- Recommends federal support of PI reimbursement and research: In
addition to a federal mandate for PI, the authors believe the U.S. government
should support reimbursement for PI products and make PI for red blood cells
(CERS pipeline product) a national research priority.
9.6 billion. This is a unique asset and someone will want to control it. I wouldn't write Apple off, but believe it will be a combination of European car companies and other European Private equity.
The parties have further agreed on certain termination fees customary in similar European transactions and payable to the other party under certain circumstances, including a change or withdrawal of the recommendation by the Board of Directors of either party, and Nokia's failure to obtain the necessary shareholder approval or certain antitrust regulatory approvals.
They design it and Foxconn makes it and distributes it. Very little risk for Nokia. It is just using its Brand to sell phones. They will most likely be Android just like the N1 tablet released this year through Foxconn. I am a Nokia shareholder and understand ALU SH are upset, but the combined company should do very well mid to long term.
Good: Nothing has changed and there are two presentations,Chugai paid 10 mil, the results are not released until Sunday. Bad: A lot of traders got in under 2$ for the run up to the results and they never hold through the results and have good profits at anything over $2.10. The ugly: The price action is a nightmare, but if I was a MM I wouldn't be doing the traders and favors and would bring it down hard so they sell now. If you are a trader you must get out before Friday's close.
I don't like the price action, but assuming no leak, it is a run for the door by traders.
31 March had Short Interest at 30 million shares ( 1/2 of all outstanding shares) Some could be covered by calls, but not most. Where will these shares come from if there is a run after the earnings call and update. Institutions which hold over 90% won't sell cheaply. Seems like the biggest gamble going to me.
Assuming HERE is a good mapping service (which it is) and assuming at least two buyers want to be in that business, the answer will be how much it costs to reproduce what HERE now has. I would assume that is north of 8-10 billion. Todays profit doesn't mean much if you need the business to add value to the business you already have (like phones, cars etc) Assuming it is really for sale (since NOK has not denied it I assume it is) bidders will be knocking on the door to have a real good look. Assets like this do not come up very often and I think there will be real interest from numerous parties. Having said all of that I am still not sure it is a good LONG TERM strategy for NOK.
If Apple bids MSFT has to bid IMO. I am hoping that we have at least 3 real bidders. Apple, MSFT and European consortium of car makers and others. Time will tell. Do you know how high MSFT went for HERE when they bought device division ?
We remain buyers of EXAS. Excellus BCBS issued a favorable coverage decision
for Cologuard today, providing EXAS an estimated 1.6M additional covered lives.
Given EXAS’ strong physician enrollment to-date and clear patient preference for a
convenient test like Cologuard, we’ve viewed insurance coverage as the last major
rate-limiter to broader adoption. However, coverage of Cologuard is ramping quickly
(Excellus follows Anthem, Tufts, and many other plans), which should help drive
volume growth in the coming quarters and years.
Another favorable coverage decision issued.
n Today, Excellus BlueCross Blue Shield issued a favorable coverage decision for
Cologuard (link here), covering the test every three years for asymptomatic
people aged 50-85.
n Excellus, headquartered in Rochester, NY, is an independent licensee of the
Blue Cross Blue Shield Association (i.e., not part of Anthem). According to the
company’s website, it provides health insurance to a total of 1.6M members.
The exchange rate shouldn't hold Nok back as it reports in Euros. If it has sales in US$ it will mean more earnings in EUROS. Everyone is saying the the strong dollar is bad for US multi nationals so how can it be also bad for NOK reporting in Euros. I think the strong dollar will help earnings not the other way around.
Physicians and patients want Cologuard; we think it’s important for EXAS
to capitalize on its early momentum.
- With ~80 reps, EXAS has reached just 6% of practicing physicians, generating
+10,000 1Q15 completed tests (+125/rep). Orders (1Q15E: +20,000, or
+1,500/week), robust physician adoption (+300/week with high conversion rate
and growing share ordering at sign-up), and high-compliance rate (+70%;
actions underway to improve) may be better demand indicators than completed
- Another 70+ reps are presently onboarding; our 2QE (15,746 completed tests)
assumes existing rep productivity doesn’t improve and new reps are half as
productive as existing ones (conservative assumptions, as no one is
counter-detailing Cologuard and its awareness is growing).
-We think it’s important for EXAS to quickly expand salesforce reach/frequency